The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
30 08 2019
Historique:
received: 27 04 2018
accepted: 30 11 2018
pubmed: 7 12 2018
medline: 2 9 2020
entrez: 4 12 2018
Statut: ppublish

Résumé

Recent studies have demonstrated the possibility of negative associations between prior influenza vaccines and subsequent influenza vaccine effectiveness (VE), depending on season and strain. We investigated this association over 4 consecutive influenza seasons (2011-2012 through 2014-2015) in Canada. Using a matched test-negative design, laboratory-confirmed influenza cases and matched test-negative controls admitted to hospitals were enrolled. Patients were stratified into 4 groups according to influenza vaccine history (not vaccinated current and prior season [referent], vaccinated prior season only, vaccinated current season only, and vaccinated both current and prior season). Conditional logistic regression was used to estimate VE; prior vaccine impact was assessed each season for overall effect and effect stratified by age (<65 years, ≥65 years) and type/subtype (A/H1N1, A/H3N2, influenza B). Overall, mainly nonsignificant associations were observed. Trends of nonsignificant decreased VE among patients repeatedly vaccinated in both prior and current season relative to the current season only were observed in the A/H3N2-dominant seasons of 2012-2013 and 2014-2015. Conversely, in 2011-2012, during which B viruses circulated, and in 2013-2014, when A/H1N1 circulated, being vaccinated in both seasons tended to result in a high VE in the current season against the dominant circulating subtype. Prior vaccine impact on subsequent VE among Canadian inpatients was mainly nonsignificant. Even in circumstances where we observed a trend of negative impact, being repeatedly vaccinated was still more effective than not receiving the current season's vaccine. These findings favor continuation of annual influenza vaccination recommendations, particularly in older adults. NCT01517191.

Sections du résumé

BACKGROUND
Recent studies have demonstrated the possibility of negative associations between prior influenza vaccines and subsequent influenza vaccine effectiveness (VE), depending on season and strain. We investigated this association over 4 consecutive influenza seasons (2011-2012 through 2014-2015) in Canada.
METHODS
Using a matched test-negative design, laboratory-confirmed influenza cases and matched test-negative controls admitted to hospitals were enrolled. Patients were stratified into 4 groups according to influenza vaccine history (not vaccinated current and prior season [referent], vaccinated prior season only, vaccinated current season only, and vaccinated both current and prior season). Conditional logistic regression was used to estimate VE; prior vaccine impact was assessed each season for overall effect and effect stratified by age (<65 years, ≥65 years) and type/subtype (A/H1N1, A/H3N2, influenza B).
RESULTS
Overall, mainly nonsignificant associations were observed. Trends of nonsignificant decreased VE among patients repeatedly vaccinated in both prior and current season relative to the current season only were observed in the A/H3N2-dominant seasons of 2012-2013 and 2014-2015. Conversely, in 2011-2012, during which B viruses circulated, and in 2013-2014, when A/H1N1 circulated, being vaccinated in both seasons tended to result in a high VE in the current season against the dominant circulating subtype.
CONCLUSIONS
Prior vaccine impact on subsequent VE among Canadian inpatients was mainly nonsignificant. Even in circumstances where we observed a trend of negative impact, being repeatedly vaccinated was still more effective than not receiving the current season's vaccine. These findings favor continuation of annual influenza vaccination recommendations, particularly in older adults.
CLINICAL TRIALS REGISTRATION
NCT01517191.

Identifiants

pubmed: 30508064
pii: 5228721
doi: 10.1093/cid/ciy1009
doi:

Substances chimiques

Influenza Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT01517191']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

970-979

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

M K Nichols (MK)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

M K Andrew (MK)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

L Ye (L)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

T F Hatchette (TF)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

A Ambrose (A)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

G Boivin (G)

Centre Hospitalier Universitaire de Québec, Québec City, Canada.

W Bowie (W)

University of British Columbia, Vancouver, Canada.

G Dos Santos (G)

Business and Decision Life Sciences, Bruxelles, Belgium.
Present affiliation: GSK, Wavre, Belgium.

M Elsherif (M)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

K Green (K)

Mount Sinai Hospital, Toronto, Ontario, Canada.

F Haguinet (F)

GlaxoSmithKline (GSK), Wavre, Belgium.

K Katz (K)

North York General Hospital, Toronto.

J Leblanc (J)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

M Loeb (M)

McMaster University, Hamilton.

D MacKinnon-Cameron (D)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

A McCarthy (A)

The Ottawa Hospital, Sudbury.

J E McElhaney (JE)

Health Sciences North Research Institute, Sudbury.

A McGeer (A)

Mount Sinai Hospital, Toronto, Ontario, Canada.

J Powis (J)

Michael Garron Hospital, Toronto.

D Richardson (D)

William Osler Health System, Brampton, Ontario.

M Semret (M)

McGill University, Montreal, Québec.

R Sharma (R)

GSK, Mississauga, Ontario, Canada.

V Shinde (V)

GSK, King of Prussia, Pennsylvania.
Present affiliation: Novavax Vaccines, Washington, D.C.

D Smyth (D)

The Moncton Hospital, New Brunswick.

S Trottier (S)

Centre Hospitalier Universitaire de Québec, Québec City, Canada.

L Valiquette (L)

Université de Sherbrooke, Québec.

D Webster (D)

Saint John Hospital Regional Hospital, Dalhousie University, New Brunswick, Canada.

S A McNeil (SA)

Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH